In a Poisson model adjusted for age, gender (including pregnancy), time, tuberculosis status and initiation CD4 count, people initiated on dolutegravir were more likely to be retained-in-care compared to those initiated on non-dolutegravir based regimens (adjusted risk ratio [aRR] 1·09 [1·04, 1·14], aRD 5·2% [2·2, 8·4], Table 2). This evidence concerns the gene CD4 and tuberculosis.